7 results
This study aims to gain insight in the in the level of fibrinolysis in patients with traumatic brain injury in the first 24 hours following trauma.Primairy objective:- To determine the 24-hour prevalence and course of fibrinolysis in patients with…
Our research group recently found that almost 50% of all OHCA patients develop hyperfibrinolysis, and found an interesting association between the degree of hyperfibrinolysis and hypoperfusion. Hypoperfusion was determined by base excess (BE),…
Primary Objective:* To evaluate ORR of avelumab in combination with talazoparib, in patients with locally advanced or metastatic solid tumors harboring BRCA1, BRCA2 or ATM defect.Secondary Objective:* To assess the overall safety and tolerability of…
The objective of this study is to support the pharma partner*s Phase III trial using Tina-quant Lipoprotein (a) RxDx assay for subject selection and optional batch testing of follow-up samples. This study is carried out to evaluate the performance…
Primary objectiveTo demonstrate that talazoparib in combination with enzalutamide is superior to placebo in combination with enzalutamide in prolonging investigator--assessed Radiographic Progression-free Survival (rPFS), in participants with mCSPC…
PrimaryTo evaluate the efficacy of single agent talazoparib in DNA damage repair (DDR) + metastatic CRPC, as measured by best objective responserate (ORR).Secondary:To evaluate efficacy with respect to the following parameters:• Time to objective…
To prove that the RECAP test has the potential of selecting patients who are sensitive to treatment with the PARP inhibitor talazoparib as measured by the PFS rate at 4 months.